AtriCure, Inc. Stock News

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced successful first-in-human treatments using its novel dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation ...

AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference. AtriCure's management is scheduled to participate i...

AtriCure, Inc. ( ATRC ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Angela Wirick - Chief Financial Officer Michael H. Carrel - CEO, President & Director Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Well, good afternoon, everyone.

AtriCure, Inc. ( ATRC ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer Conference Call Participants Marissa Bych - Gilmartin Group LLC John Young - Canaccord Genuity Corp., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Marie Thibault - BTIG, LLC, Resear...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2025 financial results. “Our third quarter results demonstrate strong execution and patient focus across the business. We are seeing continued...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the first patient was enrolled and treated in the Box Lesion Creation with Left Atrial Appendage Exclusion to Reduce the Occurrence of New-onset Atrial...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in upcoming investor conferences. AtriCure's management is scheduled to participate in a fireside discussion at the ...